Stocks News

LAST PRICE
33.0000
TODAY'S CHANGE (%)
Trending Up0.8000 (2.4845%)

Bid / Lots
31.7700/ 1
Ask / Lots
34.0000/ 5
Open / Previous Close
32.6000 / 32.2000
Day Range
Low 32.3700
High 33.4700
52 Week Range
Low 5.9300
High 38.1200
Volume
375,639
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 27, 2024
- DJ Edgewise Therapeutics Is Maintained at Buy by Truist Securities, from 12:10PM ET on Wednesday Nov 27, 2024 by Dow Jones
  12:10PM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: EWTX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 27, 2024 12:10 ET (17:10 GMT)
- Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating, from 7:33AM ET on Wednesday Nov 27, 2024 by MT Newswires
  7:33AM ET on Wednesday Nov 27, 2024 by MT Newswires
  Companies Mentioned: EWTX
  07:33 AM EST, 11/27/2024 (MT Newswires) -- Edgewise Therapeutics (EWTX) has an average rating of buy and mean price target of $45.86, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major ba...
Nov 26, 2024
- Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, from 6:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  6:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: EWTX
  
  Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
  BOULDER, Colo.--(BUSINESS WIRE)--November 26, 2024--
  Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET.
Nov 22, 2024
- DJ Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group, from 9:53AM ET on Friday Nov 22, 2024 by Dow Jones
  9:53AM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: EWTX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 22, 2024 09:53 ET (14:53 GMT)
Nov 8, 2024
- RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating, from 9:57AM ET on Friday Nov 08, 2024 by MT Newswires
  9:57AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: EWTX
  09:57 AM EST, 11/08/2024 (MT Newswires) -- Edgewise Therapeutics (EWTX) has an average rating of Buy and price targets ranging from $33 to $51, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research ...

Nov 26, 2024
- SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference, from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: SWTX
- RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target, from 6:22AM ET on Tuesday Nov 26, 2024 by MT Newswires
  6:22AM ET on Tuesday Nov 26, 2024 by MT Newswires
  Companies Mentioned: DYN
- DJ Dyne Therapeutics Initiated at Outperform by RBC Capital, from 5:12AM ET on Tuesday Nov 26, 2024 by Dow Jones
  5:12AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: DYN
Nov 22, 2024
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Nov 22, 2024 by Dow Jones
  4:05PM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: VERA
Nov 21, 2024
- DJ Vera Therapeutics Initiated at Overweight by Wells Fargo, from 8:14AM ET on Thursday Nov 21, 2024 by Dow Jones
  8:14AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: VERA
Nov 20, 2024
- DJ SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group, from 12:10PM ET on Wednesday Nov 20, 2024 by Dow Jones
  12:10PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: SWTX
Nov 18, 2024
- Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: VERA
- Press Release: Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: VERA
Nov 14, 2024
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by PR Newswire
  8:00AM ET on Thursday Nov 14, 2024 by PR Newswire
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by CNW Group
  8:00AM ET on Thursday Nov 14, 2024 by CNW Group
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX

Edgewise Therapeutics Inc
NASDAQ:EWTXUnited States

Search Criteria

Nov 27, 2024

DJ Edgewise Therapeutics Is Maintained at Buy by Truist Securities, from 12:10PM ET on Wednesday Nov 27, 2024 by Dow Jones

Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating, from 7:33AM ET on Wednesday Nov 27, 2024 by MT Newswires

Nov 26, 2024

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, from 6:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 22, 2024

DJ Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group, from 9:53AM ET on Friday Nov 22, 2024 by Dow Jones

Nov 8, 2024

RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating, from 9:57AM ET on Friday Nov 08, 2024 by MT Newswires

Peers Headlines

Nov 26, 2024

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference, from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target, from 6:22AM ET on Tuesday Nov 26, 2024 by MT Newswires

DJ Dyne Therapeutics Initiated at Outperform by RBC Capital, from 5:12AM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 22, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Nov 22, 2024 by Dow Jones

Nov 21, 2024

DJ Vera Therapeutics Initiated at Overweight by Wells Fargo, from 8:14AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

DJ SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group, from 12:10PM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 18, 2024

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones

Press Release: Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 14, 2024

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by PR Newswire

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by CNW Group